High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma

References

• Swerdlow SH, Campo E, Harris NL, et al WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
   Google Scholar
• Dreyling M, Hiddemann W. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Curr Opin Oncol 2008;20:487–494.
   PubMed Web of Science ®Google Scholar
• Herrmann A, Hoster E, Zwingers T, et al Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511–518.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, et al Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803–3809.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, et al High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Pinotti G, et al Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257–262.
   PubMed Web of Science ®Google Scholar
• Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, et al The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997;99:842–847.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, et al Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005;23:6364–6369.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001;13:342–347.
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, et al Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–2387.
   PubMed Web of Science ®Google Scholar
• Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 2009;115:1041–1048.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, et al Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925–934.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Raderer M, Wohrer S, et al Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269–2271.
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al Report on the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860–1861.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Collett D. Modelling survival data in medical research. London: Chapman & Hall; 1994. p. 26.
   Google Scholar
• Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. New York: John Wiley; 1996.
   Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0, 2003. Available from: http://ctep.cancer.gov/reporting/ctc.html.
   Google Scholar
• Hoster E, Dreyling M, Klapper W, et al A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Epner EM, Unger J, Miller T, et al A multicenter trial of hyperCVAD + Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007;110(Suppl. 1):121a (Abstract 387).
   Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, et al Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344–349.
   PubMed Web of Science ®Google Scholar
• Mead GM, Barrans SL, Qian W, et al A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008;112:2248–2260.
   PubMed Web of Science ®Google Scholar